What are my alternatives to knee replacement?
Compare nonsurgical knee arthritis care, injection choices, and selected surgical alternatives—with evidence, limits, and questions for your clinician.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsEstablished care
Dietary Changes and Weight Loss
Everyday nutrition. Weight care when appropriate.
Who might it suit?
For: People seeking healthier eating; weight-loss care when appropriate and medicines only when eligible.
Not for: A normal-weight person seeking a joint-repair injection.
Limits and important cautions
STEP 9 involved obesity and moderate knee OA. It does not establish the same joint benefit for tirzepatide, normal-weight patients, hip OA, or cartilage repair.
What happens, how long, and what could it cost?
- What happens
- Review eating patterns, goals, health history, and whether medication is appropriate.
- When might I notice a change?
- Changes are assessed over time; weight and joint symptoms may not change together.
- How long might benefit last?
- Long-term habits and follow-up matter. A medicine is a separate treatment decision.
- Repeat treatment
- Discuss ongoing support and what happens if medication is stopped or not tolerated.
- Activity and recovery
- Ask who provides follow-up, what symptoms need urgent attention, and what restrictions apply to you.
- Ask for a complete estimate
- Consultation, dietary support, medicine, monitoring, and follow-up.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
THE EVIDENCE IN CONTEXT
Strong lifestyle support; drug evidence is product-specific
Read the 3 selected references
- ACR/Arthritis Foundation: OA management ↗
2019 guideline, published in 2020. Recommendations vary by joint; it predates many newer trials.
- Bliddal et al.: semaglutide in obesity and knee OA ↗
STEP 9 studied semaglutide 2.4 mg with lifestyle counseling in obesity and moderate knee OA. Industry-funded; not a tirzepatide or hip OA trial.
- Jastreboff et al.: SURMOUNT-1 tirzepatide trial ↗
Demonstrated weight loss in obesity/overweight with eligibility criteria. Industry-funded; not a trial of joint repair or OA pain treatment.
FDA status
Approval depends on the medicineNutrition counseling is not an FDA-approved drug treatment. Wegovy (semaglutide) and Zepbound (tirzepatide) have weight-management indications for eligible patients; this does not establish approval to repair cartilage or treat osteoarthritis. Compounded versions are not FDA-approved.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.What do professional guidelines say?
AAOS: Supports sustained weight loss for overweight or obese people with knee OA.
ACR: Strongly recommends weight loss for overweight or obese people with knee or hip OA.
Will Medicare cover it?
Plan and indication dependent. Arthritis alone is not a covered indication for a GLP-1.